Effect of Statin Therapy on Abdominal Aortic Aneurysm Growth Rate and Mortality: A Systematic Review and Meta-analysis
To explore the effects of statin therapy with the abdominal aortic aneurysm (AAA) growth rate and mortality.
Findings from the Viborg Vascular (VIVA) trial show a mortality benefit of multi-faceted vascular screening which was mainly ascribed to the initiation of prophylactic medication. However, the pharmacological preventive potential, which exists when individuals have a positive screening test result and do not already use statins and anti-platelet agents, has not been analysed. The aim of this study was to investigate factors associated with a pharmacological preventive potential of statins and anti-platelet agents among attenders vascular screening for abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD).
CONCLUSION: Future vascular screening programmes might benefit from tailoring information to subgroups who are more likely to benefit from screening but less likely to accept an offer. PMID: 32063462 [PubMed - as supplied by publisher]
Introduction - Extensive reactive oxygen and nitrogen species (ROS/RNS, also reactive species) production is a mechanism involved in abdominal aortic aneurysm (AAA) development.1 White blood cells (WBC) are a known source of reactive species.2 Its production is possibly decreased by statins, thereby reducing AAA growth rate.3 We investigated reactive species production in circulating WBC of AAA patients and the effect of statins on its production.
We read with great interest the study by O'Donnell et al,1 which investigated the risk factors of postoperative renal dysfunction after open repair of abdominal aortic aneurysm (AAA) in a large retrospective cohort.
We thank Drs Yoon and Kim for their interest in our study and the higher risk for acute kidney injury (AKI) after open repair of juxtarenal abdominal aortic aneurysms in patients taking statins preoperatively. Our understanding of the interaction between statins and postoperative renal function is constantly evolving, as both observational and randomized trials have met with mixed results. Importantly, previous studies showed that initiating statins in the perioperative period was associated with higher rates of postoperative AKI, whereas long-term statin use was associated with lower risk of renal complications.
Abstract: Statins have been suggested in previous studies to play a protective role in experimental cerebral aneurysm (CA) models; however, no evidence supports that the application of statins can protect against aneurysm rupture in humans, and the risks of lipid levels and aneurysms remain unknown. Therefore, this meta-analysis aimed to summarize and update the epidemiological evidence to systematically assess the relationships of statin therapy and hyperlipidemia with the incidence, rupture, postrepair mortality, and all-cause mortality of abdominal aortic aneurysm (AAA) and CA. Related studies were initially retrieved...
This study is a retrospective review of Cochrane CENTRAL database, MEDLINE, and Embase through June 15, 2018.
Adherence to antiplatelet and statin therapy in participants diagnosed with abdominal aortic aneurysm (AAA) or peripheral arterial disease (PAD) was examined in a vascular screening trial.
CONCLUSION: In a vascular screening trial, six of every 10 non-users initiated preventive treatment; among these, the adherence rate was 57-60%. Among users at baseline, the five year adherence to antiplatelet and statin treatment exceeded 80%. The effectiveness of screening initiatives might be improved by measures to improve the fulfilment of preventive medication. PMID: 30393062 [PubMed - as supplied by publisher]